Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer

被引:100
作者
Boerner, AR
Weckesser, M
Herzog, H
Schmitz, T
Audretsch, W
Nitz, U
Bender, HG
Mueller-Gaertner, HW
机构
[1] Univ Hosp Dusseldorf, Dept Nucl Med, Dusseldorf, Germany
[2] City Hosp Dusseldorf, Dept Senol, Dusseldorf, Germany
[3] Univ Hosp Dusseldorf, Dept Obstet & Gynaecol, Dusseldorf, Germany
关键词
breast cancer; fluorine-18; fluorodeoxyglucose; positron emission tomography; tumour-to-nontumour ratio; contrast parameters;
D O I
10.1007/s002590050381
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) has proven useful in the differentiation of various tumour entities, including breast cancer. In patients with primary breast cancer we performed a 3-h imaging protocol to examine possible improvements in tumour detectability and image contrast. Twenty-nine patients with primary breast cancer with a diameter of greater than or equal to 2 cm that was demonstrated to be malignant by biopsy or surgery were injected with 370-740 MBq F-18-FDG and scanned in the prone position. Data were acquired 0-40 min, 1.5 h and 3.0 h after injection. After correction for measured attenuation, decay and scatter and iterative reconstruction, standardised uptake values (SUVs) and tumour-to-non-tumour and tumour-to-organ ratios were calculated. Visual analysis was performed using transverse, sagittal and coronal slices as well as 3D reprojection images. Tumour-to-non-tumour and tumour-to-organ ratios were significantly higher for the 3-h images than for the 1.5-h images. SUVs did not increase to the same extent. Lesion detectability was 83% in 1.5-h images compared to 93% in 3-h images. We conclude that tumour contrast in breast cancer is improved by starting the PET acquisition at 3 h p.i. rather than at 1.5 h p.i.
引用
收藏
页码:226 / 230
页数:5
相关论文
共 33 条
  • [1] Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
    Adams, S
    Baum, RP
    Stuckensen, T
    Bitter, K
    Hör, G
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) : 1255 - 1260
  • [2] EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET
    ADLER, LP
    CROWE, JP
    ALKAISI, NK
    SUNSHINE, JL
    [J]. RADIOLOGY, 1993, 187 (03) : 743 - 750
  • [3] Avril N, 1997, J NUCL MED, V38, P1186
  • [4] Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
    Avril, N
    Dose, J
    Janicke, F
    Bense, S
    Ziegler, S
    Laubenbacher, C
    Romer, W
    Pache, H
    Herz, M
    Allgayer, B
    Nathrath, W
    Graeff, H
    Schwaiger, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (06) : 1848 - 1857
  • [5] Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)fluoro-2-deoxy-D-glucose
    Avril, N
    Dose, J
    Janicke, F
    Ziegler, S
    Romer, W
    Weber, W
    Herz, M
    Nathrath, W
    Graeff, H
    Schwaiger, M
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) : 1204 - 1209
  • [6] Does fluorine-18 fluorodeoxyglucose metabolic imaging of tumours benefit oncology?
    Brock, CS
    Meikle, SR
    Price, P
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1997, 24 (06) : 691 - 705
  • [7] BROWN RS, 1993, CANCER, V72, P2979, DOI 10.1002/1097-0142(19931115)72:10<2979::AID-CNCR2820721020>3.0.CO
  • [8] 2-X
  • [9] Bruce D M, 1995, Eur J Surg Oncol, V21, P280, DOI 10.1016/S0748-7983(95)91492-7
  • [10] Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer:: a preliminary observation
    Crippa, F
    Seregni, E
    Agresti, R
    Chiesa, C
    Pascali, C
    Bogni, A
    Decise, D
    De Sanctis, V
    Greco, M
    Daidone, MG
    Bombardieri, E
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (10) : 1429 - 1434